Identification of prodrug, active drug, and metabolites in an ADEPT clinical study - PubMed (original) (raw)

Clinical Trial

. 1993 Jan-Jun;22(1-3):9-26.

doi: 10.1007/BF03033864.

Affiliations

• PMID: 7889545
• DOI: 10.1007/BF03033864

Clinical Trial

Identification of prodrug, active drug, and metabolites in an ADEPT clinical study

C J Springer et al. Cell Biophys. 1993 Jan-Jun.

Abstract

Antibody-directed enzyme prodrug therapy (ADEPT) involves two phases. The first is an antibody-enzyme conjugate that localizes to tumor. The second phase is a prodrug that is administered when the enzyme-conjugate has cleared from blood and other nontumor tissues. In the pilot-scale clinical trial, the prodrug has been measured--in the plasma of patients, by liquid chromatography (HPLC) and by liquid chromatography-mass spectrometry (LC-MS). Active drug has been detected and metabolites identified. An indirect measurement of enzyme-conjugate in the plasma of patients has also been developed.

PubMed Disclaimer

Similar articles

• A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
  Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH. Francis RJ, et al. Br J Cancer. 2002 Sep 9;87(6):600-7. doi: 10.1038/sj.bjc.6600517. Br J Cancer. 2002. PMID: 12237768 Free PMC article. Clinical Trial.
• Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
  Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG, Bagshawe KD. Blakey DC, et al. Cell Biophys. 1993 Jan-Jun;22(1-3):1-8. doi: 10.1007/BF03033863. Cell Biophys. 1993. PMID: 7889535
• Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
  Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ. Martin J, et al. Cancer Chemother Pharmacol. 1997;40(3):189-201. doi: 10.1007/s002800050646. Cancer Chemother Pharmacol. 1997. PMID: 9219501 Clinical Trial.
• Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
  Springer CJ, Niculescu-Duvaz I. Springer CJ, et al. Anticancer Drug Des. 1995 Jul;10(5):361-72. Anticancer Drug Des. 1995. PMID: 7639927 Review.
• Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
  Bagshawe KD, Sharma SK, Springer CJ, Rogers GT. Bagshawe KD, et al. Ann Oncol. 1994 Dec;5(10):879-91. doi: 10.1093/oxfordjournals.annonc.a058725. Ann Oncol. 1994. PMID: 7696159 Review.

Cited by

• A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
  Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH. Francis RJ, et al. Br J Cancer. 2002 Sep 9;87(6):600-7. doi: 10.1038/sj.bjc.6600517. Br J Cancer. 2002. PMID: 12237768 Free PMC article. Clinical Trial.
• Targeted prodrug design to optimize drug delivery.
  Han HK, Amidon GL. Han HK, et al. AAPS PharmSci. 2000;2(1):E6. doi: 10.1208/ps020106. AAPS PharmSci. 2000. PMID: 11741222 Free PMC article. Review.
• Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
  Springer CJ, Poon GK, Sharma SK, Bagshawe KD. Springer CJ, et al. Cell Biophys. 1994;24-25:193-207. doi: 10.1007/BF02789230. Cell Biophys. 1994. PMID: 7736524 Clinical Trial.
• Bioengineering strategies for designing targeted cancer therapies.
  Alexander-Bryant AA, Vanden Berg-Foels WS, Wen X. Alexander-Bryant AA, et al. Adv Cancer Res. 2013;118:1-59. doi: 10.1016/B978-0-12-407173-5.00002-9. Adv Cancer Res. 2013. PMID: 23768509 Free PMC article. Review.
• Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
  Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Dostalek M, et al. Clin Pharmacokinet. 2013 Feb;52(2):83-124. doi: 10.1007/s40262-012-0027-4. Clin Pharmacokinet. 2013. PMID: 23299465 Review.

References

1. 1. J Med Chem. 1990 Feb;33(2):677-81 - PubMed
2. 1. Br J Cancer. 1987 Nov;56(5):531-2 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842-6 - PubMed
4. 1. Br J Cancer. 1988 Dec;58(6):700-3 - PubMed
5. 1. Dis Markers. 1991 May-Aug;9(3-4):233-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database